A Phase 3 interventional study of mycophenolate mofetil (MMF) and cyclosporine A (CsA) in Heart Transplantation, sponsored by Hoffmann-La Roche. Completed at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-29.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will investigate the efficacy and safety of CellCept (1.5-2g/day po), in combination with a standard care regimen of cyclosporine A (trough level 150-200ng/mL) and steroids, in patients receiving a heart transplant. The anticipated time on study treatment is 24 weeks.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received mycophenolate mofetil (MMF) 1.0 grams (g), orally (PO), twice daily (BID) from within 24 hours of transplantation through Week 24. Participants also received an initial loading dose of cyclosporine A (CsA) 4 to 6 milligrams per kilogram (mg/kg) within 48 hours of transplantation, adjusted thereafter to a blood trough concentration of 150 to 300 nanograms per milliliter (ng/mL) through Week 24. Participants also received corticosteroids as per the practice of each participating center.
Drug: mycophenolate mofetil (MMF) · Drug: cyclosporine A (CsA) · Drug: corticosteroids
1.0 g PO BID
Also known as: CellCept
Initial loading dose of 4 to 6 mg/kg within 48 hours of transplantation, adjusted thereafter to a blood trough concentration of 150 to 300 ng/mL
As per the practice of each participating center
Percentage of Participants With Biopsy Proven Acute Rejection (BPAR) by Week
Percentage of participants with BPAR of greater than or equal to (≥) International Society of Heart and Lung Transplant (ISHLT) Grade III. The ISHLT graded symptoms on a scale of Grade 0 through VI. Grade 0 equals (=) no rejection. Grade IA = regional (perivascular or interstitial) infiltration and no necrosis, and grade IB = dissemination but little infiltration and no necrosis. Grade II = 1 focus of invasive infiltration with or without (+/-) associated cardiomyocyte necrosis. Grade IIIA = 2 or more foci of invasive infiltration +/- associated cardiomyocyte necrosis, and grade IIIB = diffuse inflammatory pathological changes associated with cardiomyocyte necrosis. Grade IV = diffuse, infiltrative multi-foci +/- edema; +/- hemorrhage; and +/-vasculitis.
Time frame: Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants With Graft Loss Within 24 Weeks of Transplantation
Time frame: Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants Requiring Use of Additional Immunosuppressants Not Specified in the Protocol Within 24 Weeks of Transplantation
Time frame: Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants Discontinuing Immunosuppressants (MMF) for More Than 14 Consecutive Days or 30 Cumulative Days Within 24 Weeks of Transplantation
Time frame: Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants Lost To Follow Up Within 24 Weeks of Transplantation
Time frame: Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants With Normal Serum Creatinine and Blood Urea Nitrogen (BUN) Values At Baseline (BL) And During Treatment
Time frame: Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants With Normal Serum Creatinine and BUN Values at Baseline and Abnormal Values During Treatment
Time frame: Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants With Abnormal Serum Creatinine and BUN Values at Baseline and Normal Values During Treatment
Time frame: Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants With Abnormal Serum Creatinine and BUN Values at Baseline and During Treatment
Time frame: Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24
| Milestone | Mycophenolate Mofetil (MMF) Plus (+) Cyclosporine A (CsA) |
|---|---|
| Started | 36 |
| Completed | 32 |
| Not completed | 4 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Death | 2 |
Percentage of participants with BPAR of greater than or equal to (≥) International Society of Heart and Lung Transplant (ISHLT) Grade III. The ISHLT graded symptoms on a scale of Grade 0 through VI. Grade 0 equals (=) no rejection. Grade IA = regional (perivascular or interstitial) infiltration and no necrosis, and grade IB = dissemination but little infiltration and no necrosis. Grade II = 1 focus of invasive infiltration with or without (+/-) associated cardiomyocyte necrosis. Grade IIIA = 2 or more foci of invasive infiltration +/- associated cardiomyocyte necrosis, and grade IIIB = diffuse inflammatory pathological changes associated with cardiomyocyte necrosis. Grade IV = diffuse, infiltrative multi-foci +/- edema; +/- hemorrhage; and +/-vasculitis.
| percentage of participants | MMF + CsA |
|---|---|
| Day 1 | 0.0 (0.00 to 0.00) |
| Week 1 | 0.0 (0.00 to 0.00) |
| Week 2 | 2.78 (0.00 to 8.42) |
| Week 4 | 2.78 (0.00 to 8.42) |
| Week 8 | 2.78 (0.00 to 8.42) |
| Week 12 | 2.78 (0.00 to 8.42) |
| Week 16 | 2.78 (0.00 to 8.42) |
| Week 20 | 2.78 (0.00 to 8.42) |
| Week 24 | 2.78 (0.00 to 8.42) |
| percentage of participants | MMF + CsA |
|---|---|
| Percentage of Participants With Graft Loss Within 24 Weeks of Transplantation | 0.0 |
| percentage of participants | MMF + CsA |
|---|---|
| Percentage of Participants Requiring Use of Additional Immunosuppressants Not Specified in the Protocol Within 24 Weeks of Transplantation | 0.0 |
| percentage of participants | MMF + CsA |
|---|---|
| Percentage of Participants Discontinuing Immunosuppressants (MMF) for More Than 14 Consecutive Days or 30 Cumulative Days Within 24 Weeks of Transplantation | 13.89 (2.02 to 25.76) |
| percentage of participants | MMF + CsA |
|---|---|
| Percentage of Participants Lost To Follow Up Within 24 Weeks of Transplantation | 0.0 |
| percentage of participants | MMF + CsA |
|---|---|
| Serum creatinine | 47.22 |
| BUN | 8.33 |
| percentage of participants | MMF + CsA |
|---|---|
| Serum creatinine | 22.22 |
| BUN | 16.67 |
| percentage of participants | MMF + CsA |
|---|---|
| Serum creatinine | 16.67 |
| BUN | 2.78 |
| percentage of participants | MMF + CsA |
|---|---|
| Serum creatinine | 13.89 |
| BUN | 72.22 |
Collected over Adverse events were assessed at Day 1, and Weeks 1, 2, 4, 8, 12, 16, 20, and 24.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MMF + CsA | — | 2/36 (5.6%) | 36/36 (100%) |
| Event | MMF + CsA |
|---|---|
| Multiple organ failureGeneral disorders | 1/36 |
| Cardiac arrestCardiac disorders | 1/36 |
| Event | MMF + CsA |
|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 17/36 |
| Elevated blood sugarInvestigations | 14/36 |
| HyperglycemiaMetabolism and nutrition disorders | 14/36 |
| TachycardiaCardiac disorders | 8/36 |
| HypertensionVascular disorders | 8/36 |
| InsomniaPsychiatric disorders | 7/36 |
| Elevated blood lipidsInvestigations | 7/36 |
| Elevated serum creatinineInvestigations | 7/36 |
| Elevated alanine aminotransferaseInvestigations | 7/36 |
| Abnormal liver function testsInvestigations | 7/36 |
Intent-to-treat (ITT) population: all enrolled participants who recieved at least 1 dose of study treatment.
| Age, Continuous(years) | MMF + CsA |
|---|---|
| Mean | 44.83 ± 11.89 |
| Sex: Female, Male(Participants) | MMF + CsA |
|---|---|
| Female | 8 |
| Male | 28 |
The record gives a start of Aug 2006, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 5 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Mycophenolic Acid · Cyclosporine